For 4QFY2017, Cadila Healthcare posted lower than expected results. The sales came in at `2,418cr (v/s. `2,800cr expected) v/s. `2,270cr in 4QFY2016, a yoy growth of 6.5%. On the operating front, the EBITDA margin came in at 16.7% v/s. 21.4% (v/s. 15.7% expected) in 4QFY2016. The GPM’s came in at 61.6% (v/s. 65.7% in 4QFY2016), which resulted in the dip in OPM. This, along with the 49.9% yoy increase in deprecation lead the Adj. net profit to register `386cr (v/s. `353cr expected) v/s. `568cr in 4QFY2016, a yoy de-growth of 32.1%. We remain Neutral.
Download Full Report View Full Report in BrowserPlease Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...